Product features:

Chapter
Gentle, double-sided adhesive wound contact layer - minimizes your patients' pain during dressing changes

Mepitel is a gentle, double-sided adhesive wound contact layer with Safetac – the original silicone adhesive contact layer that minimizes dressing change pain. It adheres gently to the skin without sticking to the moist wound. This allows you to easily remove the dressing without damaging the skin or the wound, making dressing changes less painful for your patients. Safetac also protects newly formed tissue and intact skin, supporting the natural healing process. The wound edges are sealed to protect the skin from maceration. Thanks to its perforated design, wound exudate drains into a secondary absorbent dressing. You can leave the dressing in place and apply topical treatments. The integrity of the dressing allows it to remain on the wound for up to 14 days, and secondary dressings can be changed without disrupting the healing process.

• Truly undisturbed healing - can remain on the wound for up to 14 days.
• Leaves no residue and retains its functional properties permanently.

Application areas of Mepitel:
Mepitel is a non-adherent wound dressing with a mesh structure (wound spacer) that allows exudate to drain away. It adheres well to the skin and protects the tissue. Mepitel is designed for a variety of exuding wounds, such as skin fissures, abrasions, sutured wounds, second-degree burns, lacerations, superficial and deep skin graft wounds, diabetic foot ulcers, and venous and arterial leg ulcers. Mepitel can also be used as a protective layer on non-exuding wounds, blisters, fragile skin, and exposed fragile tissue. The open structure of Mepitel allows for the application of topical ointments to the wound when clinically indicated. You can use Mepitel in combination with Mesorb or—for highly exuding wounds—with Mextra Superabsorbent, with Tubifast fixation, and under compression bandages. Mepitel can also be used in conjunction with negative pressure wound therapy.

Source: www.molnlycke.de
As of January 2024